Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

里奥西瓜特 医学 cGMP特异性磷酸二酯酶5型 西地那非 打开标签 肺动脉高压 内科学 抢救疗法 随机对照试验 心脏病学 重症监护医学 慢性血栓栓塞性肺高压
作者
Marius M. Hoeper,Hikmet Al‐Hiti,Raymond L. Benza,Sung‐A Chang,Paul A. Corris,J. Simon R. Gibbs,Ekkehard Grünig,P Jansa,James R. Klinger,David Langleben,Vallerie V. McLaughlin,G. Meyer,Jaquelina Sonoe Ota Arakaki,Andrew J. Peacock,Tomás Pulido,Stephan Rosenkranz,Carmine Dario Vizza,Anton Vonk Noordegraaf,R.J. White,Mikyung Chang
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (6): 573-584 被引量:128
标识
DOI:10.1016/s2213-2600(20)30532-4
摘要

Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of riociguat and PDE5i in these patients are needed. The aim of this trial was to assess the effects of switching to riociguat from PDE5i therapy versus continued PDE5i therapy in patients with PAH at intermediate risk of 1-year mortality.Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) was an open-label, randomised controlled trial in 81 hospital-based pulmonary hypertension centres in 22 countries. The study enrolled patients aged 18-75 years with symptomatic PAH at intermediate risk of 1-year mortality (based on the European Society for Cardiology-European Respiratory Society guideline thresholds for WHO functional class and 6-min walk distance [6MWD]) who were receiving treatment with a PDE5i with or without an endothelin receptor antagonist for at least 6 weeks before randomisation. Patients were excluded if they had been previously treated with riociguat, had used prostacyclin analogues or prostacyclin receptor agonists within 30 days before randomisation, had clinically significant restrictive or obstructive parenchymal lung disease, or had left heart disease. Patients were randomly assigned (1:1) to remain on PDE5i treatment (oral sildenafil [≥60 mg per day] or oral tadalafil [20-40 mg per day]; the PDE5i group) or to switch to oral riociguat (up to 2·5 mg three times per day; the riociguat group), using an interactive voice and web response system, stratified by cause of PAH. The primary endpoint was clinical improvement by week 24, defined as an absence of clinical worsening and prespecified improvements in at least two of three variables (6MWD, WHO functional class, and N-terminal prohormone of brain natriuretic peptide), analysed using last observation carried forward in all randomly assigned patients with observed values at baseline and week 24 who received at least one dose of study medication (the full analysis set). Secondary endpoints included clinical worsening events. The trial has been completed and is registered with ClinicalTrials.gov, NCT02891850.Between Jan 11, 2017, and July 31, 2019, 293 patients were screened, of which 226 patients were randomly assigned to the riociguat group (n=111) or to the PDE5i group (n=115). 211 patients completed the study and 14 patients discontinued (seven in each group). One patient assigned to the PDE5i group did not receive treatment, so 225 patients were included in the safety analysis, and one further patient in the PDE5i group had missing components of the composite primary endpoint at baseline, so 224 patients were included in the full analysis set. The primary endpoint was met by 45 (41%) of 111 patients in the riociguat group and 23 (20%) of 113 patients in the PDE5i group; odds ratio [OR] 2·78 (95% CI 1·53-5·06; p=0·0007). Clinical worsening events occurred in one (1%) of 111 patients in the riociguat group (hospitalisation due to worsening PAH) and 10 (9%) of 114 patients in the PDE5i group (hospitalisation due to worsening PAH [n=9]; disease progression [n=1]; OR 0·10 [0·01-0·73]; p=0·0047). The most frequently occurring adverse events were hypotension (15 [14%]), headache (14 [13%]), and dyspepsia (10 [9%]) in the riociguat group, and headache (eight [7%]), cough (seven [6%]), and upper respiratory tract infection (seven [6%]) in the PDE5i group. Serious adverse events were reported in eight (7%) of 111 patients in the riociguat group and 19 (17%) of 114 patients in the PDE5i group. During the study, four patients died in the PDE5i group, one of them during the safety follow-up period.Switching to riociguat from PDE5i treatment, both of which act via the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway, could be a strategic option for treatment escalation in patients with PAH at intermediate risk of 1-year mortality.Bayer AG, Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wp完成签到,获得积分10
3秒前
splemeth完成签到,获得积分10
3秒前
雪白的紫翠完成签到 ,获得积分10
4秒前
哈哈完成签到,获得积分10
5秒前
淡定访琴完成签到,获得积分10
7秒前
大力云朵完成签到,获得积分10
9秒前
ADcal完成签到 ,获得积分10
9秒前
9秒前
tony完成签到,获得积分10
9秒前
苏苏完成签到,获得积分10
11秒前
WuFen完成签到 ,获得积分10
12秒前
淘宝叮咚完成签到,获得积分10
12秒前
高高从云完成签到 ,获得积分10
13秒前
情怀应助唐唐采纳,获得10
14秒前
科研肥料完成签到,获得积分10
15秒前
每天都在找完成签到,获得积分10
15秒前
桐桐应助zzw采纳,获得20
15秒前
15秒前
吕布完成签到,获得积分10
16秒前
16秒前
ChenYifei完成签到,获得积分10
20秒前
qq发布了新的文献求助10
20秒前
Smiley完成签到 ,获得积分10
23秒前
hzauhzau完成签到 ,获得积分10
23秒前
白桃完成签到 ,获得积分10
25秒前
小八统治世界完成签到 ,获得积分10
26秒前
Lotus完成签到,获得积分10
26秒前
btyyl完成签到,获得积分10
27秒前
屈岂愈发布了新的文献求助10
28秒前
29秒前
HH发布了新的文献求助10
30秒前
葵葵完成签到,获得积分10
31秒前
高大莺完成签到 ,获得积分10
33秒前
zzw发布了新的文献求助20
34秒前
幸福果汁完成签到,获得积分10
35秒前
量子星尘发布了新的文献求助10
35秒前
谢谢谢谢谢谢谢谢完成签到 ,获得积分10
36秒前
Akim应助biofresh采纳,获得30
36秒前
长安发布了新的文献求助10
37秒前
38秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022